AKERS ACQUISITION SUB, INC. – Trademark Portfolio

Entity Type: 03

AKERS ACQUISITION SUB, INC. holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 1 filings in this category. The portfolio also extends into Class 10 (Medical Apparatus) across 2 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include BREATHSCAN. The owner is based in THOROFARE, NJ.

201 GROVE ROAD

THOROFARE, NJ 08086

2 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

AKERS ACQUISITION SUB, INC.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

1
Chemicals (1 filing)

Chemical products for industry, science, photography, agriculture, horticulture and forestry

10
Medical Apparatus (1 filing)

Surgical, medical, dental and veterinary apparatus and instruments

Frequently Asked Questions

How many trademarks does AKERS ACQUISITION SUB, INC. have?

AKERS ACQUISITION SUB, INC. has 2 U.S. trademarks filed with the USPTO. Of these, 1 registered, 1 cancelled.

What trademark classes does AKERS ACQUISITION SUB, INC. file in?

AKERS ACQUISITION SUB, INC. files trademarks across 2 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 10 (Medical Apparatus). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.

What are AKERS ACQUISITION SUB, INC.'s most well-known trademarks?

AKERS ACQUISITION SUB, INC.'s registered trademark portfolio includes well-known marks such as BREATHSCAN. These are among 1 currently registered trademark in the portfolio.

What is AKERS ACQUISITION SUB, INC.'s trademark registration success rate?

AKERS ACQUISITION SUB, INC. has a 50% trademark registration rate, with 1 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.